KDR and renal cell carcinoma associated with Xp11.2 translocations/TFE3 gene fusions: Cabozantinib is a TKI targeting VEGFR, MET, RET, KIT, and AXL19 currently approved for the treatment of metastatic RCC based on the results of two prospective studies, which only included patients with clear cell histology.20,21 Retrospective studies have reported the efficacy of cabozantinib in cohorts of non-clear cell RCC patients, with objective response rates (ORR) of approximately 30% and median times to treatment failure (TTF) of 6.7 months (95%CI 5.5-8.6).22-24 However, these studies included different histologies, precluding specific assessment of the benefit of cabozantinib in TRCC.